TriSalus Life Sciences (NASDAQ: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, has chosen to expand their headquarters in Westminster, Colorado. With over 18,000 patients served since they began operations in 2009, TriSalus has steadily proved itself as a committed and leading innovator in the life sciences field.
The company is positioned to further develop their proprietary TriNav and Pressure Enabled Drug Delivery (PEDD) technologies. TriSalus is expanding and updating their headquarters facility in Westminster in order to meet increased demand. TriSalus and the City of Westminster are proud to have partnered on this important project.
The City of Westminster has been an excellent strategic location for the company thanks to its central location along the US-36 Corridor, granting access to Boulder’s globally recognized technology community and the robust metro Denver economy.
